Clinical trials: PERIPHERAL VASCULAR DISEASE
Peripheral Vascular Disease, Embolism and Thrombosis
Registry of AngioJet Use in the Peripheral Vascular System
The Registry involves the collection of information for research and educational purposes only on the use of AngioJet in the peripheral vascular system.
- Conditions
- Peripheral Vascular Disease, Embolism and Thrombosis, Venous Thrombosis
- Trial name
- PEARLII (NCT01086215)
- Where
- 36 sites in United States, Canada and 3 more
- Volunteers
- 500 people
- Sponsor
- Boston Scientific Corporation
Peripheral Arterial Disease
Heat Therapy to Reduce Pain and Improve Walking Tolerance
The purpose of this study is to investigate whether exposure to heat therapy improves calf muscle oxygenation and enhances walking tolerance in patients with symptomatic Peripheral Arterial Disease (PAD).
- Trial name
- NCT03435835
- Testing
- Heat Therapy (HT)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Indiana University
Peripheral Arterial Disease, Vascular Disease, Peripheral
Disrupt PAD+ Study With the Shockwave Medical M5+ Peripheral IVL System
Prospective, multi-center, single-arm study of the M5+ Peripheral IVL system to treat calcified peripheral arteries.
- Trial name
- Disrupt PAD+ (NCT04585763)
- Testing
- Shockwave Medical M5+ Peripheral Intravascular Lithotripsy (IVL)
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 37 people
- Sponsor
- Shockwave Medical, Inc.
Diabetes Mellitus, Diabetic Foot Disease
Gremlin-1 and Wagner Classification: Potential Biomarker for Amputation in Diabetic Foot Patients
The aim of the approach to diabetic foot patients is to heal the wound, mobilize the patient, increase the quality of life, and reduce DA-related amputations as much as possible.
- Conditions
- Diabetes Mellitus, Diabetic Foot Disease, Diabetic Foot Ulcer, Diabetic Neuropathy
- Trial name
- NCT06753604
- Where
- Turkey (Türkiye)
- Volunteers
- 85 people
- Sponsor
- Seyma Acik
Breast Cancer, Chronic Myeloproliferative Disorders
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00293384
- Testing
- Aprepitant, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Peripheral Vascular Disease
Bard® LifeStent® Vascular Stent Delivery System Study
The purpose of this study is to evaluate the effectiveness and safety of a new delivery system for the Bard® LifeStent® Vascular Stent System.
- Trial name
- NCT01179984
- Testing
- Bard® LifeStent® Vascular Stent System
- Where
- 8 sites in Austria, Germany
- Volunteers
- 76 people
- Sponsor
- C. R. Bard
Critical Limb Ischemia
Evaluation of the Tissue Genesis® Icellator Cell Isolation System™ to Treat Critical Limb Ischemia
The purpose of this study is to determine the safety and effectiveness of the Tissue Genesis® Icellator Cell Isolation System™ in Critical Limb Ischemia.
- Trial name
- CLI-DI (NCT02234778)
- Testing
- TGI SVF material via intramuscular injection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Tissue Genesis
Multiple Myeloma and Plasma Cell Neoplasm
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by…
- Trial name
- NCT00014508
- Testing
- sargramostim, cyclophosphamide, cyclosporine
- Where
- 12 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Peripheral Artery Disease
Far Infrared Therapy on Peripheral Artery Disease in Hemodialysis Patients
The prevalence of peripheral artery disease (PAD) defined as ankle-brachial index (ABI) less than 0.9 was about 15~30% in patients with end stage renal disease (ESRD), which was higher than those with normal renal function.
- Trial name
- NCT01095549
- Testing
- WSTM TY101 FIR emitter (Far infrared therapy)
- Where
- 2 sites in Taiwan
- Volunteers
- 300 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Intermittent Claudication
Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers
The study is designed to evaluate the bioequivalency between the test formulations of extended-release tablet of cilostazol (PMR) administered once-daily and the reference formulation of immediate-release tablet of cilostazol…
- Trial name
- NCT03480321
- Testing
- Cilostazol 100 mg, PMR 150 mg, PMR 200 mg
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Ischemic Heart Disease, Ischemic Stroke
Study to Compare 2 Doses of Polycap Versus Single Dose of Polycap With or Without Pottasium
This is a randomized double blind 2x2 factorial controlled trial to evaluate efficacy tolerability of low strength Polycap versus two doses of low strength Polycap in patients with stable cardiovascular disease in reducing blood…
- Conditions
- Ischemic Heart Disease, Ischemic Stroke, Peripheral Vascular Disease, Type 2 Diabetes Mellitus
- Trial name
- TIPSK (NCT01404078)
- Testing
- Single Dose Polycap, Double dose Polycap
- Volunteers
- 518 people
- Sponsor
- St. John's Research Institute
Aneurysm Arterial, Peripheral Arterial Disease
Safety and Performance of POLYTHESE® Vascular Prosthesis
POLYTHESE® study is a retrospective, observational, multicentre, case series which examine short and long-term outcomes of using POLYTHESE®.
- Conditions
- Aneurysm Arterial, Peripheral Arterial Disease, Marfan Syndrome, Arterial Dissections
- Trial name
- NCT05516043
- Testing
- Implantation with POLYTHESE®
- Where
- 3 sites in France
- Volunteers
- 256 people
- Sponsor
- Perouse Medical
Diffuse Large B Cell Lymphoma, Follicular Lymphoma
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
This is a Phase I, multi-center, open-label, FIH study comprising of 2 study parts (Phase Ia, Phase Ib). The Phase Ia (dose escalation) part of the study is designed to determine the safety, tolerability, and maximum tolerated…
- Conditions
- Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
- Trial name
- NCT04018248
- Testing
- BR101801 (Phase Ia), BR101801 (Phase Ib)
- Where
- 9 sites in United States, South Korea
- Volunteers
- 26 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Peripheral Artery Disease, Atherosclerosis
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
To evaluate the safety and effectiveness of the Ranger™ Paclitaxel Coated Balloon for treating lesions located in the superficial femoral and proximal popliteal arteries (SFA/PPA).
- Conditions
- Peripheral Artery Disease, Atherosclerosis, Artery Diseases, Peripheral, Plaque, Atherosclerotic
- Trial name
- RANGER II SFA (NCT03064126)
- Testing
- RANGER™ Paclitaxel Coated Balloon, Paclitaxel, Standard Balloon Angioplasty
- Where
- 67 sites in United States, Austria and 4 more
- Volunteers
- 440 people
- Sponsor
- Boston Scientific Corporation
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
This pilot trial studies different high-dose chemotherapy regimens with or without total-body irradiation (TBI) to compare how well they work when given before autologous stem cell transplant (ASCT) in treating patients with…
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT00536601
- Testing
- etoposide, cyclophosphamide, carmustine
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Roswell Park Cancer Institute
Peripheral Vascular Diseases
Efficacy Study of Stenting, Paclitaxel Eluting Balloon or Atherectomy to Treat Peripheral Artery Disease
The purpose of the study is to evaluate the efficacy of stenting after dilation with or without paclitaxel-eluting balloon or atherectomy in patients with symptomatic peripheral artery disease.
- Trial name
- ISAR-STATH (NCT00986752)
- Testing
- Stenting (Smart Stent), Stenting after PEB (Smart Stent, Invatec), Atherectomy (SilverHawk device)
- Where
- 2 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Endothelial Dysfunction
The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis
We will study the hypothesis that long-term Tekturna treatment will improve endothelial function and the production and function of endothelial progenitor cells (EPCs) in patients with early atherosclerosis.
- Trial name
- NCT01067326
- Testing
- Aliskiren
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Insulin-like Growth Factor I, Insulin-like Growth Factor II
Neurotrophic Factors in Cerebrospinal Fluid in Diabetic Patients With Polyneuropathy
Background: The pathogenetic factors underlying development of diabetic polyneuropathy (DP) remain unclear. Reduced neurotrophic stimulation has been proposed as a possible mechanism.
- Conditions
- Insulin-like Growth Factor I, Insulin-like Growth Factor II, Diabetes Complications, Polyneuropathies
- Trial name
- NCT01718015
- Where
- Denmark
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Peripheral Arterial Disease
Study of the SilverHawk™ /TurboHawk™ Plaque Excision Systems Used With SpiderFX to Treat Calcified Peripheral Arterial Disease (DEFINITIVE Ca++)
This is a multi-center, non-randomized, single arm study of the SilverHawk™ /TurboHawk™ plaque excision systems when used in conjunction with SpiderFX™ embolic protection device in treatment of moderate to severely calcified…
- Trial name
- NCT00733135
- Testing
- SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device
- Volunteers
- 133 people
- Sponsor
- Medtronic Endovascular
Peripheral Artery Disease, Atherosclerosis
Telephone Health Coaching and Remote Exercise Monitoring for Peripheral Artery Disease
Peripheral artery disease (PAD) is the third most prevalent cardiovascular disease worldwide, with over 200 million people affected. Most prominent symptom is leg pain while walking known as intermittent claudication.
- Conditions
- Peripheral Artery Disease, Atherosclerosis, Peripheral Arterial Disease, Arterial Occlusive Diseases
- Trial name
- TeGeCoach (NCT03496948)
- Testing
- TeGeCoach
- Where
- 3 sites in Germany
- Volunteers
- 1,982 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf